Utidelone is under clinical development by BioStar Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer.

Utidelone is under clinical development by BioStar Pharmaceuticals and currently in Phase I for Ovarian Cancer.

Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling. Nature Cancer , 2025; DOI: 10.1038/s43018-024-00882-2 Cite This Page : ...

To address this gap, researchers analyzed gene expression within individual tumor cells. This study reports the molecular features and interactions of tumor and immune cells associated with two ...

This important study reveals a critical role of the transcription factor NR2F2 in mouse fetal Leydig cell (FLC) differentiation. With elegantly carried out experiments, the authors provide compelling ...

The adoptive transfer of TCR-T cells specific to neoantigens preferentially exhibits potent cytotoxicity to tumor cells and has shown promising efficacy in various preclinical human cancers. In this ...

In a study published in Nature Communications, Lewis Zhichang Shi, M.D., Ph.D., and University of Alabama at Birmingham colleagues show, for the first time, how HIF1α in T cells is key for ...

FSH and testosterone act synergistically on Sertoli cells to promote Sertoli cell function ... However, even if the patient has received cancer treatment before being referred to the transplant ...

Citation: Gene inhibition provides potential way to overcome cancer cells' resistance to chemotherapy drug cisplatin (2024, December 16) retrieved 3 January 2025 from https://medicalxpress.com ...